

Machine Learning Detection of Obstructive Hypertrophic Cardiomyopathy Using a Wearable Biosensor

AHA 2017 Late Breaking Basic Science

Eric M. Green MD, PhD, Reinier van Mourik PhD, Charles Wolfus JD,
Stephen B. Heitner MD, Onur Dur PhD, Marc J. Semigran MD





MyoKardia

Hypertrophic cardiomyopathy




- Inherited disease of heart muscle characterized by hypertrophy without a systemic etiology
- Characteristic hemodynamic abnormalities related to hypercontractility (with or without LVOT obstruction) and impaired relaxation
- Variable age of onset and disease natural history
- Substantial risk of heart failure, afib/stroke and sudden death



Most Individuals with HCM Are Currently Undiagnosed



- Population studies estimate HCM prevalence at least 1:500
- Medicare claims data show ~100K under care
 - ~**16%** diagnosis rate
 - Most patients (~80%) with sudden death and HCM are previously undiagnosed
- Early diagnosis allows for risk stratification for sudden death and other complications
- Diagnosis limited by non-specific symptoms and requirement for expensive, hospital-based testing



Maron, B. J. et al. (1995).. *Circulation*, 92(4), 785–789.

Maron, M. S. et al. (2016). *The American Journal of Cardiology*, 117(10), 1651–1654.

Aro, A. L. , et al. (2017). *Circulation*, 136(17), 1665–1667.



How can we increase the detection rate for HCM?

**Could we develop a method that is non-invasive,
does not require a skilled operator and can be
widely disseminated?**

Characteristic Hemodynamics of Obstructive HCM (oHCM)







Normal

LVOT obstruction

Acoustic phonography

Carotid pulsations

Doppler echo




Frank and Braunwald *Circulation* 1968


Photoplethysmography Detects Peripheral Bloodflow Patterns



PPG is a non-invasive optical method to detect blood volume changes in the microvascular bed at the skin surface.



Millasseau et al. 2006,
Hypertension



Tamura et al., 2014,
Electronics




PIONEER-HCM Digital Health Substudy



- *Develop a classifier for oHCM PPG signals prior to treatment*
- *Evaluate changes in oHCM PPG signals on treatment*

19 oHCM patients



86 controls

5 minute PPG, paired with echo



iPad/mobile apps to collect and transmit data

Train a machine learning classifier for oHCM in a training cohort

Validate oHCM classifier using validation cohort


PIONEER-HCM is an ongoing phase 2 open-label study of multiple doses of mavacamten in patients with oHCM

Pulsewave Morphology Differs Between oHCM and Healthy Subjects



Pulsewave morphology in oHCM consistent with turbulent bloodflow and beat-to-beat variability associated with dynamic LVOT obstruction

An Accurate Machine Learning Classifier for oHCM



	oHCM	control
Predicted oHCM	18	4
Predicted control	1	82

Overall Accuracy = 0.95


Sensitivity = 0.95

Specificity = 0.95


oHCM Classifier Receiver/Operator Characteristics



Training and cross-validation (n=12 oHCM, 46 controls)



Validation (N=7 oHCM, 40 controls)



Summary and Next Steps



Summary


- We demonstrate proof of principle that a wearable biosensor and machine learning algorithm can identify patients with obstructive HCM

Next Steps

- Further validation in large data sets and across hardware platforms
 - Consider combination with other HCM screening modalities such as EKG
- Evaluation of changes in response to mavacamten treatment in PIONEER
- Application to non-obstructive HCM patients
 - Is there an identifiable signature in this population?
- A tool for increased disease understanding
 - Longitudinal measurement to detect dynamic LVOT obstruction in HCM patients outside the clinic, correlate with symptoms, identify stimuli
 - Could identify candidates for SRT or intensified medical therapy based on hemodynamics outside clinic setting




Sensors



Suite of Algorithms

Multiplexed platform for passive disease screening in HCM and beyond

Acknowledgments



Charles Wolfus
Jonathan Fox
Stu Heminway
Marek Wolter

Brianne Leary
Durga Bobba
Patrick Smith

Amanda Kovach
Michael Grimm
Linda Scott
Marc Semigran

Onur Dur
Reinier van Mourik
Clark Seninger
Laurie Lind
Abe Carter

PIONEER-HCM patients, investigators and site staff

